Design and Evaluation of Autophagy-Inducing Particles for the Treatment of Abnormal Lipid Accumulation.

Zagkou, Stavroula; Marais, Valentine; Zeghoudi, Narimane; Guillou, Edouard Le; Eskelinen, Eeva-Liisa; Panasyuk, Ganna; Verrier, Bernard; Primard, Charlotte

Zagkou, Stavroula; Marais, Valentine; Zeghoudi, Narimane; Guillou, Edouard Le; Eskelinen, Eeva-Liisa; Panasyuk, Ganna; Verrier, Bernard; Primard, Charlotte.

Afiliação

Zagkou S; Adjuvatis, 60 Avenue Rockefeller, 69008 Lyon, France.
Marais V; Laboratory of Tissue Biology and Therapeutic Engineering, CNRS UMR 5305, Université Claude Bernard Lyon 1, CEDEX 7, 69367 Lyon, France.
Zeghoudi N; Adjuvatis, 60 Avenue Rockefeller, 69008 Lyon, France.
Guillou EL; Adjuvatis, 60 Avenue Rockefeller, 69008 Lyon, France.
Eskelinen EL; INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, Université Paris Cité, 75015 Paris, France.
Panasyuk G; Institute of Biomedicine, University of Turku, 20520 Turku, Finland.
Verrier B; INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, Université Paris Cité, 75015 Paris, France.
Primard C; Adjuvatis, 60 Avenue Rockefeller, 69008 Lyon, France.

Pharmaceutics ; 14(7)2022 Jun 29.

Article em En | MEDLINE | ID: mdl-35890275

Palavras-chave

Tat-Beclin peptide; autophagy; liver targeting; non-alcoholic fatty liver disease; polylactic acid; polymeric nanoparticles

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Pharmaceutics Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França